Early alpha-synuclein lipoxidation in neocortex in Lewy body diseases.
Previous studies in Lewy body diseases (LBDs), including Parkinson's disease (PD) and Dementia with Lewy bodies (DLB), have shown oxidative stress damage more extended than the expected for the distribution of Lewy pathology. Since malondialdehyde (MDA) can form adducts with lysine residues of proteins, MDA-Lys immunoprecipitation and alpha-synuclein immunoblotting has been carried out in frontal cortex and substantia nigra homogenates from five patients with PD, five DLB, three iPD and seven aged-matched controls to decipher the extent of lipoxidized alpha-synuclein in LBDs. MDA-Lys-lipoxidation of alpha-synuclein in the substantia nigra and frontal cortex has been found in all DLB and PD cases examined, but also in the frontal cortex in 3/3 and in the substantia nigra in 2/3 cases with iPD. In addition, one control case had MDA-Lys-modified alpha-synuclein in the frontal cortex, and another in the substantia nigra. This work provides evidence of extended lipoxidative modification of alpha-synuclein in LBDs. Moreover, it demonstrates that alpha-synuclein lipoxidation is an early event in LBDs which precedes alpha-synuclein solubility modification and aggregation, and formation of Lewy bodies and neurites.
Dalfó
Esther
E
Institut de Neuropatologia, Servei Anatomia Patològica, IDIBELL-Hospital Universitari de Bellvitge, Spain.
Ferrer
Isidre
I
D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D047468:Immunoprecipitation; D020961:Lewy Body Disease / Q000473:pathology*; D008239:Lysine / Q000031:analogs & derivatives / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D019579:Neocortex / Q000378:metabolism*; D010084:Oxidation-Reduction / Q000187:drug effects; D010300:Parkinson Disease / Q000378:metabolism / Q000473:pathology; D051844:alpha-Synuclein / Q000378:metabolism*
C464486:N(epsilon)-(malondialdehyde)lysine; D051844:alpha-Synuclein; D008239:Lysine